In an article from earlier this year, Richard Ramko of Life Science Leader laid out the current landscape of early-stage biopharma financing. The unprecedented levels of investments throughout 2020 and early 2021 began to dip in the latter half of the year and early 2022. However, Ramko argues that the stage is still set for success in biotech, as there is still high demand for innovations from the industry.
According to Ramko, “As the 40-year-old biotech industry reaches maturity, the already-unprecedented rate of innovation present in today’s landscape will accelerate further. Long-in-development technologies, like mRNA and cell and gene therapies, have been proven to work or will soon come to fruition. With their ability to not just treat, but to cure, diseases, mRNA and cell and gene therapies are likely to dramatically expand the possibilities and demand for healthcare.”
To read more, click here.
(Source: Life Science Leader, May 2nd, 2022)
